NASDAQ:FHTX Foghorn Therapeutics Q1 2025 Earnings Results & Report $2.07 0.00 (0.00%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$2.06 0.00 (-0.24%) As of 11/13/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Foghorn Therapeutics met analyst earnings expectations and beat on revenue in its Q1 2025 results, released May 14, 2025. The company reported EPS of -$0.30 versus the -$0.30 consensus estimate, while revenue of $5.95 million topped the $4.96 million estimate by $990.00 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2025Report DateMay 14, 2025TimeBefore Market OpensConference Call7:00 AM ET Foghorn Therapeutics EPS ResultsActual EPS-$0.30Consensus EPS -$0.30Beat/MissMet ExpectationsOne Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersFoghorn Therapeutics Revenue ResultsActual Revenue$5.95 millionExpected Revenue$4.96 millionBeat/MissBeat by +$990.00 thousandYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Foghorn Therapeutics Q1 2025 Earnings FAQ Did Foghorn Therapeutics beat earnings estimates for Q1 2025? Foghorn Therapeutics (NASDAQ:FHTX) reported earnings of -$0.30 per share for Q1 2025, matching the consensus estimate of -$0.30. The report was announced on Wednesday, May 14, 2025. What was Foghorn Therapeutics' revenue for Q1 2025? Foghorn Therapeutics reported revenue of $5.95 million for Q1 2025, against a consensus estimate of $4.96 million. Foghorn Therapeutics Earnings HeadlinesFoghorn Therapeutics Inc. (NASDAQ:FHTX) Stock Now Rated "Hold" by Wall Street Analysts58 minutes ago | americanbankingnews.comHC Wainwright Analysts Increase Earnings Estimates for FHTXNovember 14 at 2:10 AM | americanbankingnews.comDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out. | Weiss Ratings (Ad)Guggenheim Sticks to Its Buy Rating for Foghorn Therapeutics (FHTX)November 12, 2026 | theglobeandmail.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTXNovember 12, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTXNovember 10, 2026 | globenewswire.comSee More Foghorn Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Foghorn Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Foghorn Therapeutics and other key companies, straight to your email. Email Address About Foghorn TherapeuticsFoghorn Therapeutics (NASDAQ:FHTX) is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for cancer. Its research centers on chromatin regulatory systems, which help control how genes are expressed and can contribute to disease when disrupted. The company’s Gene Traffic Control platform is designed to identify drug targets within these systems. Foghorn has developed investigational programs targeting chromatin regulators, including components of the BAF complex; its candidates remain in development and are not approved medicines. Founded in 2015 and based in Cambridge, Massachusetts, Foghorn has pursued research collaborations with other pharmaceutical companies, including Eli Lilly. Adrian Gottschalk has served as the company’s chief executive officer.View Foghorn Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/13Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCerebras Q3 Results: How Much More Proof Does Wall Street Need?Applied Materials Beats and Raises, But Investors Stay Unconvinced3 Power and Grid Stocks That Could Keep Growing Even if AI Spending SlowsYETI Beat on Earnings, But Its Sales Tell a Different Story Upcoming Earnings Walt Disney (11/17/2026)Home Depot (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.